Research study Program year 2023 Source: CMS Open Payments

A Randomised, Double-Blind, Placebo Controlled, Parallel Group Phase I

Research payments

$703,816

191 payments

Through program year 2023, $703,816 in research payments was reported against A Randomised, Double-Blind, Placebo Controlled, Parallel Group Phase I, across 191 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$155,543	70
2022	Research	$457,067	90
2021	Research	$91,206	31

Breakdown

Who paid Research payments · program years 2021–2023

GlaxoSmithKline, LLC. $703,816 191 payments

Who received the money Research payments · program years 2021–2023

Gi Reviewers LLC Organisation paid for research $594,146 160 payments
Bioclinica INC Organisation paid for research $109,670 31 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

5 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.